Circadian variation of mineral and bone parameters in end-stage renal disease

Journal of Nephrology

Volumn 28, Issue 3, 2015, Pages 351-359

  Trivedi, Hariprasad ^a   Szabo, Aniko ^a   Zhao, Shi ^a   Cantor, Tom ^b   Raff, Hershel ^a,c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Scantibodies Laboratory Inc   (United States)

^c ST LUKE S MEDICAL CENTER   (United States)

Author keywords

Calcium; Circadian variation; End stage renal disease; Parathyroid hormone; Phosphate

Indexed keywords

CALCIFEDIOL; CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; UREA; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR; PHOSPHATE; PTH PROTEIN, HUMAN; VITAMIN D;

ADULT; ARTICLE; BLOOD ANALYSIS; BONE PARAMETERS; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DIETARY COMPLIANCE; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; MINERAL PARAMETERS; PARAMETERS; ANALOGS AND DERIVATIVES; BLOOD; BONE; CASE CONTROL STUDY; KIDNEY FAILURE, CHRONIC; METABOLISM; PATHOPHYSIOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; BIOMARKERS; BONE AND BONES; CALCIUM; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME; VITAMIN D;

EID: 84930197788     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-014-0124-6     Document Type: Article

References (21)

1. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl 3):S1–S202
2. Block GA, Klassen PS, Lazarun JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218
3. Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC, ARO Investigators (2011) Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transpl 26:1948–1955
4. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD (2006) Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70:771–780
5. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M (2009) Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20:388–396
6. Portale AA, Halloran BP, Morris RC (1987) Dietary intake of phosphate modulates the circadian rhythm in serum concentration of phosphorus. Implication for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest 80:1147–1154
7. Kemp GJ, Blumsohn A, Morris BW (1992) Circadian changes in plasma phosphate concentration, urinary phosphate excretion, and cellular phosphate shifts. Clin Chem 38:400–402
8. Fuleihan GE, Klerman EB, Brown EN, Choe Y, Brown EM, Czeisler CA (1997) The parathyroid hormone circadian rhythm is truly endogenous––a general clinical research study. J Clin Endocrinol Metab 82:281–286
9. Nigwekar SU, Bhan I, Thadhani R (2012) Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis 60:139–156
10. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592
11. Raff H, Trivedi H (2013) Circadian rhythm of salivary cortisol, plasma cortisol, and plasma ACTH in end-stage renal disease. Endocr Connect 2(1):23–31. doi:10.1530/EC-12-0058
12. Carruthers BM, Copp DH, McKintosh HW (1964) Diurnal variation in urinary excretion of calcium and phosphate and its relation to blood levels. J Clin Lab Med 63:959–968
13. Fraser WD, Logue FC, Christie JP, Cameron DA, O’Reilly DS, Beastall GH (1994) Alterations of the circadian rhythm of intact parathyroid hormone following a 96-hour fast. Clin Endocrinol 40:523–528
14. Agrawal R, Knochel JP (2000) Hypophosphatemia and hyperphosphatemia. In: Brenner BM (ed) The kidney, 6th edn. WB Saunders, Philadelphia, pp 1071–1128
15. Porter A, Gilmartin C, Srisakul U, Arruda J, Akkina S (2013) Prevalence of 25-OH vitamin D deficiency in a population of hemodialysis patients and efficacy of an oral ergocalciferol supplementation regimen. Am J Nephrol 37:568–574
16. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2008) Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transpl 23:3670–3676
17. Jean G, Terrat J-C, Vanel T, Hurot J-M, Lorriaux C, Mayor B, Chazot C (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transpl 24:2792–2796
18. Seiler S, Lucisano G, Ege P, Fell LH, Rogacev KS, Lerner-Gräber A, Klingele M, Ziegler M, Fliser D, Heine GH (2013) Single FGF-23 measurement and time-averaged plasma phosphate levels in hemodialysis patients. Clin J Am Soc Nephrol 8:1764–1772
19. Stadie WC (1994) The relation of insulin to phosphate metabolism. Yale J Biol Med 16(5):539–559
20. Riley MS, Schade DS, Eaton RP (1979) Effects of insulin infusion on plasma phosphate in diabetic patients. Metabolism 28:191–194
21. Schmitt C, Borzych D, Nau B, Wühl E, Zurowska A, Schaefer F (2009) Dialytic phosphate removal: a modifiable measure of dialysis efficacy in automated peritoneal dialysis. Perit Dial Int 29:465–471